Stock listing
NASDAQ:QNCX Quince Therapeutics, Inc. Stock
Home listing (NASDAQ) of Quince Therapeutics, Inc.
Follow Quince Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:QNCX
$33.08 USD +0.25 (+0.8%)
Close on Oct 23, 2026
- Day range
- $27.40 – $33.21 USDOct 23, 2026
- Volume
- 89,800 sharesOct 23, 2026
- Market cap
- $33.64M USDAt the close on Oct 23, 2026 · price × 1.02M shares outstanding
- 52-week range
- $15.10 – $910.00 USDLowest and highest trades, Oct 24, 2025 – Oct 23, 2026
- Traded on an average day
- $1.25M USDMedian day 26,282 shares · last 3 months, Jul 23, 2026 – Oct 23, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:QNCX · Home | $33.08 USD | +0.25 (+0.8%) | 89,800 | $31.61 | $33.21 | $27.40 | $32.83 | Close on Oct 23, 2026 |
Daily closes
Last 3 months, Jul 23, 2026 – Oct 23, 2026 · NASDAQ:QNCX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $33.08 | +0.25 | +0.8% | $31.61 | $33.21 | $27.40 | 89,800 | |
| $32.83 | -1.85 | -5.3% | $35.70 | $35.70 | $31.34 | 166,100 | |
| $34.68 | -5.59 | -13.9% | $39.54 | $40.98 | $34.00 | 216,300 | |
| $40.27 | +5.82 | +16.9% | $34.99 | $41.00 | $34.79 | 317,100 | |
| $34.45 | +2.42 | +7.6% | $31.17 | $34.61 | $31.01 | 41,600 | |
| $32.03 | -1.20 | -3.6% | $31.18 | $34.93 | $31.18 | 11,600 | |
| $33.23 | +3.23 | +10.8% | $28.99 | $33.71 | $28.99 | 9,000 | |
| $30.00 | +2.13 | +7.6% | $26.72 | $30.23 | $26.72 | 26,900 | |
| $27.87 | -4.53 | -14.0% | $28.51 | $30.80 | $25.13 | 84,300 | |
| $32.40 | +0.67 | +2.1% | $29.51 | $32.61 | $26.50 | 76,900 | |
| $31.73 | +2.37 | +8.1% | $30.50 | $37.00 | $29.84 | 138,700 | |
| $29.36 | +2.64 | +9.9% | $27.10 | $29.80 | $26.65 | 31,900 | |
| $26.72 | -0.09 | -0.3% | $26.74 | $27.95 | $26.72 | 12,703 | |
| $26.81 | -1.29 | -4.6% | $27.68 | $28.15 | $26.81 | 27,826 | |
| $28.10 | -1.10 | -3.8% | $29.00 | $29.78 | $28.00 | 22,095 | |
| $29.20 | -1.48 | -4.8% | $30.20 | $31.06 | $29.20 | 68,380 | |
| $30.68 | -0.33 | -1.1% | $31.99 | $31.99 | $29.20 | 20,920 | |
| $31.01 | -0.16 | -0.5% | $31.97 | $32.59 | $30.62 | 10,678 | |
| $31.17 | +2.17 | +7.5% | $28.70 | $32.00 | $26.45 | 21,795 | |
| $29.00 | -2.00 | -6.5% | $30.00 | $31.20 | $26.90 | 40,796 | |
| $31.00 | +1.00 | +3.3% | $30.40 | $31.00 | $29.98 | 10,336 | |
| $30.00 | -0.15 | -0.5% | $30.81 | $30.81 | $29.60 | 10,861 | |
| $30.15 | -1.20 | -3.8% | $31.01 | $31.01 | $29.03 | 7,589 | |
| $31.35 | +0.35 | +1.1% | $32.79 | $32.99 | $30.50 | 24,000 | |
| $31.00 | +1.52 | +5.2% | $29.46 | $31.00 | $28.54 | 13,675 | |
| $29.48 | +2.47 | +9.1% | $27.20 | $30.00 | $27.20 | 48,836 | |
| $27.01 | -0.16 | -0.6% | $27.17 | $27.83 | $26.62 | 11,883 | |
| $27.17 | -1.675 | -5.8% | $27.39 | $28.50 | $25.78 | 49,302 | |
| $28.85 | +0.255 | +0.9% | $28.57 | $29.99 | $27.15 | 15,930 | |
| $28.59 | -0.96 | -3.2% | $29.28 | $29.28 | $27.00 | 33,567 | |
| $29.55 | +0.59 | +2.0% | $28.88 | $30.44 | $28.88 | 11,341 | |
| $28.96 | -1.355 | -4.5% | $30.00 | $30.00 | $28.31 | 3,634 | |
| $30.32 | +0.815 | +2.8% | $29.47 | $31.03 | $28.76 | 10,329 | |
| $29.50 | -1.82 | -5.8% | $31.88 | $31.88 | $29.01 | 12,708 | |
| $31.32 | +0.77 | +2.5% | $30.53 | $33.40 | $30.00 | 37,864 | |
| $30.55 | -1.60 | -5.0% | $32.96 | $32.96 | $30.23 | 10,987 | |
| $32.15 | +0.04 | +0.1% | $32.92 | $33.05 | $31.96 | 15,484 | |
| $32.11 | -0.46 | -1.4% | $33.03 | $33.48 | $32.11 | 16,489 | |
| $32.57 | -1.18 | -3.5% | $34.04 | $34.04 | $31.47 | 34,168 | |
| $33.75 | +1.25 | +3.8% | $32.91 | $35.34 | $31.85 | 27,170 | |
| $32.50 | +1.19 | +3.8% | $31.99 | $32.86 | $29.95 | 16,517 | |
| $31.31 | +0.38 | +1.2% | $31.90 | $32.01 | $31.31 | 13,714 | |
| $30.93 | -2.55 | -7.6% | $32.40 | $33.69 | $30.93 | 17,450 | |
| $33.48 | -0.45 | -1.3% | $33.00 | $33.51 | $32.50 | 5,729 | |
| $33.93 | +1.82 | +5.7% | $32.77 | $34.09 | $32.57 | 9,537 | |
| $32.11 | -2.46 | -7.1% | $34.57 | $35.15 | $31.62 | 23,333 | |
| $34.57 | +1.66 | +5.0% | $32.89 | $35.23 | $31.25 | 23,403 | |
| $32.91 | -1.21 | -3.5% | $33.00 | $34.86 | $32.27 | 28,623 | |
| $34.12 | +0.08 | +0.2% | $34.95 | $35.41 | $33.08 | 38,991 | |
| $34.04 | +1.63 | +5.0% | $31.78 | $35.20 | $31.78 | 26,183 | |
| $32.41 | +1.15 | +3.7% | $30.89 | $33.74 | $30.89 | 34,484 | |
| $31.26 | -1.47 | -4.5% | $32.92 | $33.26 | $30.04 | 44,134 | |
| $32.73 | +2.08 | +6.8% | $31.50 | $33.11 | $30.50 | 35,224 | |
| $30.65 | +0.45 | +1.5% | $30.00 | $31.47 | $29.68 | 33,702 | |
| $30.20 | +0.66 | +2.2% | $29.92 | $30.77 | $29.25 | 30,356 | |
| $29.54 | +0.66 | +2.3% | $29.17 | $30.32 | $28.55 | 26,120 | |
| $28.88 | +1.47 | +5.4% | $27.16 | $29.99 | $27.16 | 42,790 | |
| $27.41 | +2.445 | +9.8% | $25.36 | $27.48 | $24.81 | 26,381 | |
| $24.97 | +1.575 | +6.7% | $23.51 | $26.62 | $23.50 | 54,412 | |
| $23.39 | +0.36 | +1.6% | $23.47 | $24.59 | $21.55 | 35,298 | |
| $23.03 | +1.03 | +4.7% | $21.81 | $23.66 | $21.76 | 58,793 | |
| $22.00 | +2.63 | +13.6% | $19.51 | $22.41 | $18.43 | 80,498 | |
| $19.37 | +1.52 | +8.5% | $17.47 | $19.37 | $17.36 | 37,630 | |
| $17.85 | -0.005 | 0.0% | $17.72 | $18.49 | $17.60 | 18,093 | |
| $17.86 | -0.425 | -2.3% | $18.40 | $18.40 | $17.51 | 15,247 | |
| $18.28 | -0.26 | -1.4% | $18.24 | $18.64 | $17.80 | 21,631 |
Splits
2 splits since 2026 · NASDAQ:QNCX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:QNCX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 9, 2026
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Latest deck · November 2026
IRulya Therapeutics — Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Oct 9, 2026
Closed $31.73 (+8.1%) on Oct 9, 2026
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Sep 17, 2026
Closed $27.01 (-0.6%) on Sep 17, 2026
Quince Therapeutics to Participate in September 2026 Investor Conferences
Sep 3, 2026
Closed $30.55 (-5.0%) on Sep 3, 2026
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Aug 14, 2026
Closed $34.04 (+5.0%) on Aug 14, 2026
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Jun 30, 2026
Closed $18.19 (-1.2%) on Jun 30, 2026
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
May 18, 2026
Closed $19.90 (-13.5%) on May 18, 2026
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Mar 30, 2026
Closed $20.20 (+14.8%) on Mar 30, 2026
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Feb 9, 2026
Closed $105.60 (+306.2%) on Feb 10, 2026
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Jan 29, 2026
Closed $54.00 (-91.5%) on Jan 29, 2026
Quince Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 51 in all · newest Oct 9, 2026 · oldest 2023
- Decks
- 4 decks · latest November 2026
Where Quince Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:QNCX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:QNCX | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 1.2×: the lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Oct 23, 2026
- Enterprise value
- −$82.34M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.84
Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics, Inc. · NASDAQ:QNCX | US$33.64M | −US$82.34M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.84 |
| Cantargia AB · OMXSTO:CANTA | US$35.54M | US$13.84M | 2.2× | 0.5× | 0.9× | 1.4× | 52.8% | 0.0× | n/a |
| Cue Biopharma, Inc. · NASDAQ:CUE | US$34.69M | −US$23.25M | n/a | −0.7× | n/a | 0.9× | −580.0% | 0.0× | 2.35 |
| B&K Corporation Limited Class H · HKEX:2396 | US$33.15M | −US$47.10M | n/a | −602× | n/a | 0.4× | n/a | 0.0× | n/a |
| Veru Inc. · NASDAQ:VERU | US$33.08M | US$9.20M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.92 |
| Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM | US$33.01M | US$5.49M | 3.1× | n/a | 0.6× | 1.3× | n/a | 0.1× | 0.71 |
| Neurizon Therapeutics Limited · ASX:NUZ | US$32.76M | US$26.54M | n/a | 2.3× | n/a | 3.9× | −61.0% | 0.3× | n/a |
| CJ Bioscience. Inc. · KRX:311690 | US$32.52M | US$1.91M | n/a | 0.7× | n/a | 1.0× | −607.2% | 0.0× | n/a |
| Transcenta Holding Limited · HKEX:6628 | US$32.41M | US$52.52M | n/a | 12.4× | n/a | 0.4× | −569.5% | 0.3× | n/a |
| Enimmune Corporation · TPEX:6564 | US$31.74M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.66M | US$29.60M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Median of the others | US$32.89M | US$11.52M | 2.6× | 0.7× | 0.7× | 1.2× | −455.3% | 0.0× | 1.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 75.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.65 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brigette Roberts | Chief Executive Officer & Board Member |
Board
| Director | Role |
|---|---|
| Brigette Roberts | Chief Executive Officer & Board Member |
| Catherine Bonuccelli | Board Member |
| Drayton Wise | Board Member |
| James E. Valentine | Board Member |
| Leone Patterson | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 11, 2026 | |
| Q2 2026 | Aug 14, 2026 · Before open | +5.0% |
| Q1 2026 | Apr 10, 2026 · After close | |
| Q4 2025 | Mar 3, 2026 | +5.0% |
| Q3 2025 | Nov 12, 2025 · After close | −1.8% |
| Q2 2025 | Aug 11, 2025 · After close | +14.4% |
| Q1 2025 | May 12, 2025 · Before open | +1.0% |
| Q4 2024 | Mar 24, 2025 · After close | −2.1% |
| Q3 2024 | Nov 13, 2024 · After close | +19.5% |
| Q2 2024 | Aug 13, 2024 · After close | −4.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 1, 2024 · After close | −3.7% |
| Q4 2023 | Feb 14, 2024 · Before open | +7.6% |
| Q3 2023 | Nov 14, 2023 · After close | −0.8% |
| Q2 2023 | Aug 3, 2023 · After close | −1.6% |
| Q1 2023 | May 15, 2023 · After close | +1.3% |
| Q4 2022 | Mar 15, 2023 · After close | −1.3% |
| Q3 2022 | Nov 9, 2022 · After close | +3.9% |
| Q2 2022 | Aug 9, 2022 · After close | +7.9% |
| Q1 2022 | May 10, 2022 · After close | −15.6% |
| Q4 2021 | Mar 1, 2022 · After close | +4.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IRulya Therapeutics — Investor Presentation (November 2026) | Investor deck | 35 slides | November 2026 |
| Investor Presentation (May 2026) | Investor deck | 32 slides | May 18, 2026 |
| Technical Presentation (May 2026) | Technical | 16 slides | May 2026 |
| Merger or Acquisition (July 2023) | Merger or acquisition | 19 slides | Jul 24, 2023 |
Financings
| Raise | Date |
|---|---|
| Private placement of series C non-voting convertible preferred stock and warrants Closed: US$115M raised · warrants that could bring up to an additional $83 million upon exercise (including… | Aug 14, 2026 |
| Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants Closed: US$11.5M raised · US$1.325 a share · Warrants at US$1.2 for 60 months · Citizens Capital Markets +2 Dealers: Citizens Capital Markets (lead), Maxim Group LLC, Brookline Capital Markets Buyers: Nantahala Capital (led the private placement); ADAR1 Capital Management; Quince senior management Insiders: Members of Quince's senior management participated Use of proceeds: Working capital and general corporate purposes, including Phase 3 NEAT trial enrollment in A-T, R&D, G&A and capital expenditures | Jun 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 142.0K | 186.0K | 322.0K | 175.0K | 344.0K | 332.0K | 188.0K | 51.0K | 45.0K |
| Gross profit | -142.0K | -186.0K | -322.0K | -175.0K | -344.0K | -332.0K | -188.0K | -51.0K | -45.0K |
| Research and development | 35.4M | 18.6M | 9.45M | 25.2M | 60.8M | 61.3M | 30.2M | 10.1M | 9.10M |
| Selling, general and administrative | 15.0M | 17.6M | 17.7M | 26.0M | 29.5M | 17.6M | 8.95M | 2.03M | 1.27M |
| Operating income | -50.4M | -57.3M | -34.6M | -52.0M | -90.3M | -78.9M | -39.2M | -12.1M | -10.4M |
| Depreciation and amortization | 142.0K | 186.0K | 322.0K | 204.0K | 344.0K | 332.0K | 188.0K | 51.0K | 45.0K |
| EBITDA | -50.3M | -57.1M | -34.3M | -51.8M | -90.0M | -78.6M | -39.0M | -12.1M | -10.3M |
| Interest expense | 568.0K | 373.0K | 2.04M | 2.19M | 957.0K | 1.64M | |||
| Income before tax | -80.8M | -56.7M | -31.6M | -51.9M | -89.9M | -76.8M | -37.0M | -12.5M | -12.2M |
| Income tax | 3.21M | 87.0K | -197.0K | -284.0K | -620.0K | 2.17M | -188.0K | 357.0K | 1.86M |
| Net income | -84.0M | -56.8M | -31.4M | -51.7M | -89.9M | -76.8M | -37.0M | -12.5M | -12.2M |
| Earnings per share, basic | -335.27 | -262.71 | -168.57 | -308.45 | -605.31 | -526.79 | -388.61 | -115.78 | -113.54 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.81M | 6.21M | 20.8M | 44.6M | 69.7M | 66.8M | 51.2M | 24.9M | 7.34M |
| Short-term investments | 11.9M | 34.6M | 54.3M | 45.6M | 37.1M | 67.0M | 48.6M | 46.8M | |
| Receivables | 3.62M | 882.0K | 993.0K | 1.00M | 1.13M | ||||
| Inventory | 2.29M | 2.25M | |||||||
| Current assets | 22.9M | 44.0M | 77.4M | 93.7M | 111.7M | 137.9M | 106.1M | 72.6M | 7.54M |
| Property, plant and equipment | 393.0K | 1.43M | 1.10M | 1.33M | 283.0K | ||||
| Goodwill | 0 | 17.6M | 0 | ||||||
| Total assets | 93.5M | 114.5M | 180.2M | 103.9M | 133.2M | 189.5M | 124.4M | 72.9M | 7.72M |
| Accounts payable | 2.22M | 2.90M | 2.03M | 570.0K | 4.91M | 3.56M | 3.08M | 495.0K | 517.0K |
| Current liabilities | 43.2M | 7.28M | 9.57M | 3.07M | 14.2M | 17.0M | 8.89M | 1.46M | 1.76M |
| Long-term debt | 14.3M | 13.4M | |||||||
| Total debt | 18.5M | 14.8M | 13.8M | 453.0K | 1.16M | 446.0K | 7.17M | ||
| Total liabilities | 129.2M | 84.3M | 95.1M | 3.32M | 14.6M | 17.2M | 8.89M | 1.46M | 28.0M |
| Shareholders' equity | -35.7M | 30.1M | 85.1M | 100.6M | 118.6M | 172.3M | 115.5M | 71.4M | -20.3M |
| Shares outstanding | 250.5K | 216.3K | 186.2K | 167.5K | 148.6K | 145.9K | 95.2K | 107.8K | 107.8K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.4M | -31.9M | -18.3M | -44.0M | -62.9M | -50.8M | -33.3M | -11.7M | -9.83M |
| Capital spending | -352.0K | -257.0K | -160.0K | -133.0K | -180.0K | -52.0K | -55.0K | -212.0K | -77.0K |
| Free cash flow | -41.8M | -32.2M | -18.5M | -44.2M | -63.1M | -50.9M | -33.3M | -11.9M | -9.90M |
| Cash from investing | 23.2M | 21.9M | -5.76M | 18.0M | 59.0M | -52.4M | -17.7M | -46.8M | -77.0K |
| Cash from financing | 17.9M | -4.78M | 143.0K | 707.0K | 6.81M | 118.9M | 77.4M | 75.9M | 7.75M |
| Share buybacks | 63.7M | 16.5M | |||||||
| Change in cash | -403.0K | -14.5M | -23.8M | -25.1M | 2.88M | 15.6M | 26.3M | 17.5M | -2.15M |
Cap table
Built by 6ix from Quince Therapeutics, Inc.’s releases · as of Aug 14, 2026
- Common shares
- 1,017,063
- Fully diluted
- 1,017,063
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,017,063 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
| Warrants · US$1.20 · expire about Jun 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,017,063 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Karen Smith Other companies: Context Therapeutics Inc. (Independent Director · Since at least Sep 4, 2024); Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Emergent BioSolutions Inc. (EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past); Jazz Pharmaceuticals plc (EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past) | Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past |
| Rajiv Patni Other companies: Septerna, Inc. (Chief Medical Officer · Since at least Aug 24, 2026); BioXcel Therapeutics, Inc. (Director · Since at least Jan 15, 2025); Reata Pharmaceuticals Inc (EVP, Chief R&D Officer · Jun 12, 2023 – Sep 26, 2023 · Past); Portola Pharmaceuticals Inc (EVP, CMO · Feb 3, 2020 – Jul 2, 2020 · Past); Adamas Pharmaceuticals Inc (Chief Medical Officer · Jun 8, 2015 – Apr 8, 2019 · Past); Ocera Therapeutics Inc (Chief Development Officer · Sep 2, 2014 – May 7, 2015 · Past) | Director · Since at least Feb 15, 2024 |
| Christopher P Lowe Other companies: Vincerx Pharma Inc (Director · May 13, 2021 – Aug 24, 2022 · Past); Anthera Pharmaceuticals Inc (CFO and Chief Business Officer · Feb 23, 2010 – May 17, 2013 · Past); Hansen Medical Inc (Interim CFO, Director · Nov 15, 2006 – Jul 27, 2016 · Past) | Interim CEO, COO & CFO · May 8, 2019 – Mar 3, 2022 · Past |
| Caryn Gordon McDowell Other companies: Revance Therapeutics, Inc. (SVP, GC & Secretary · May 1, 2018 – Feb 15, 2020 · Past); Cytokinetics, Incorporated (GC & Chief Compliance Officer · May 18, 2016 – Feb 27, 2018 · Past) | Chief Legal & Adm. Officer · May 5, 2020 – Jun 6, 2022 · Past |
| Charles Ryan Other companies: Polaryx Therapeutics, Inc. (Director · Since at least Jan 29, 2026); Neurotrope Inc (Director · Nov 24, 2020 – Dec 1, 2020 · Past) | President · Since at least Sep 1, 2023 |
| David Lamond Other companies: Lucira Health Inc (Director · Feb 4, 2021 – Jun 1, 2022 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – May 24, 2022 · Past) | Director · Since at least May 8, 2019 |
| Casey Lynch Other companies: Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past) | Chief Executive Officer, Director · May 8, 2019 – Jan 3, 2022 · Past |
| Christopher J. Senner Other companies: Exelixis, Inc. (Executive Vice President and Chief Financial Officer · Since at least Jul 15, 2015) | Director · Since at least May 8, 2019 |
| June Bray Other companies: BioXcel Therapeutics, Inc. (Director · Since at least Mar 1, 2021) | Director · Since at least Jun 9, 2022 |
| Kevin Young Other companies: Gilead Sciences, Inc. (Chief Operating Officer · May 24, 2016 – Feb 15, 2018 · Past) | Director · May 8, 2019 – Jun 8, 2020 · Past |
All 22 people
| Person | Seat |
|---|---|
| Luca Benatti Other companies: Intercept Pharmaceuticals Inc (Director · Jul 17, 2014 – Nov 8, 2023 · Past) | Director · Since at least Oct 23, 2023 |
| Brendan Hannah | CBO, COO & CCO · Since at least May 19, 2022 |
| Brigette Roberts | Chief Executive Officer & Board Member · Since at least May 18, 2026 |
| Catherine Bonuccelli | Board Member · Since at least Oct 9, 2026 |
| Dirk Thye | CEO and CMO, Director · Since at least Jun 18, 2025 |
| Drayton Wise | Board Member · Since at least Oct 9, 2026 |
| Guenter Janhofer | Chief Scientific Officer · Oct 23, 2023 – Oct 23, 2023 · Past |
| James Valentine | Board Member · Since at least Oct 9, 2026 |
| Kristen Gafric | SVP, Legal & Administration · May 8, 2019 – Feb 6, 2020 · Past |
| Leone Patterson | Board Member · Since at least Oct 9, 2026 |
| Margaret McLoughlin | Director · Since at least May 8, 2019 |
| Philip S Low | Director · May 19, 2022 – May 19, 2022 · Past |
Log in to ask 6ix AI your own questions about Quince Therapeutics, Inc.